Patient P-01767
Therapy response
Favorable
Tolerance
Favorable
GI state
Favorable
Inflammatory state
Favorable
Nutritional resilience
Declining
Discontinuation risk
30%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 21 DT-01 recommended — Dosing / Timing Recommendation DT-01
- Day 22 Patient accepted — Started DT-01 in the companion
- Day 27 No meaningful change — Dosing / Timing Recommendation DT-01
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- GI instability+4
- Nutritional resilience-4
What helped?
- Dosing / Timing Recommendation DT-01Day 21Result: no meaningful change
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion24.5/100
improving · -11.7 vs previous 14 d
Toxicity
Blood20.7/100
worsening · +1.6 vs previous 14 d
Sleep quality
Wearable53/100
improving · +6.8 vs previous 14 d
Energy level
Daily log5.6/10
improving · +0.8 vs previous 14 d
Stress level
Daily log4.7/10
improving · -0.6 vs previous 14 d
Steps
Wearable5,533
improving · +309 vs previous 14 d
Adherence
Companion95.8 %
stable · +0.4 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 74 from the failing basin, 16 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
Would not help
- DT-01 Dosing / Timing Recommendationalready tried, no meaningful change
- Keep spicy lowGI +5.6 next day on high-intake days · n 19
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Spicy / capsaicin+5.6detractor · 95%
- Alcohol-1.7no signal · 28%
- Insoluble fibre-0.7no signal · 15%
- Histamine load-0.6no signal · 15%
- Dietary fat load-0.4no signal · 15%
- Simple carbohydrates-0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑40
- DNACYP2D6 poor metabolizer → higher exposure
- Inflammatory signalling ↓25
- DNAIL6 -174 variant raises baseline inflammatory tone
- Autonomic recovery ↓25
- WearableResting HR 77 bpm
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 3.6 · butyrate capacity 62/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 44 ms
- Sleep
- 7.5 h
- Steps
- 4,879
- Resting HR
- 71 bpm
Daily log: GI score 25, nutritional resilience 60, adherence 96.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01571 | 48% | S13 | SC-12 | improved | 57 |
| P-01804 | 45% | S19 | AD-05 | improved | 61 |
| P-01430 | 42% | S05 | CR-01 | improved | 54 |
| P-01724 | 42% | S10 | DT-01 | improved | 63 |
| P-01455 | 38% | S01 | GI-04 | improved | 61 |
| P-01593 | 37% | S10 | HY-01 | improved | 56 |
| P-01342 | 36% | S11 | DT-01 | improved | 48 |
| P-01346 | 36% | S12 | DT-01 | improved | 52 |
| P-01555 | 36% | S06 | GI-04 | improved | 56 |
| P-01752 | 36% | S20 | DT-01 | improved | 50 |
| P-01861 | 36% | S12 | HY-01 | improved | 47 |
| P-01798 | 34% | S08 | NP-02 | improved | 78 |